Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.60 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 264.76K shares, a 54.37% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.34M shares, a 38.19% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 219.15K shares, a 45.76% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 439.85K shares, a 244.71% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.02M shares, a 2.39% increase from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.90M shares, a 40.78% increase from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.48M shares, a 54.37% increase from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.26M shares, a 10.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 264.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.60M shares 10-Q · filed 2026-08-06 | 2.82M shares derived: sum of 3 quarters · filed 2026-08-06 | 3.26M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.34M shares 10-Q · filed 2026-05-07 | 2.56M shares derived: sum of 2 quarters · filed 2026-05-07 | 3.00M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.58M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 219.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 659.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.24M shares derived: sum of 3 quarters · filed 2026-02-26 | 5.02M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 439.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.02M shares derived: sum of 2 quarters · filed 2025-11-06 | 4.80M shares 10-Q · filed 2025-11-06 | 5.20M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 580.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 4.36M shares 10-Q · filed 2025-08-11 | 4.76M shares derived: sum of 3 quarters · filed 2025-08-11 | 4.89M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 3.78M shares 10-Q · filed 2025-05-06 | 4.18M shares derived: sum of 2 quarters · filed 2025-05-06 | 4.31M shares derived: sum of 3 quarters · filed 2025-05-06 | 4.51M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 404.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 531.65K shares derived: sum of 2 quarters · filed 2025-02-27 | 731.11K shares derived: sum of 3 quarters · filed 2025-02-27 | 4.90M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 127.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 327.06K shares derived: sum of 2 quarters · filed 2024-11-06 | 4.50M shares 10-Q · filed 2024-11-06 | 4.59M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 199.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 4.37M shares 10-Q · filed 2024-08-01 | 4.46M shares derived: sum of 3 quarters · filed 2024-08-01 | 4.59M shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 4.17M shares 10-Q · filed 2024-05-07 | 4.26M shares derived: sum of 2 quarters · filed 2024-05-07 | 4.39M shares derived: sum of 3 quarters · filed 2024-05-07 | 4.68M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 86.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 217.45K shares derived: sum of 2 quarters · filed 2024-02-28 | 504.39K shares derived: sum of 3 quarters · filed 2024-02-28 | 3.48M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 130.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 417.49K shares derived: sum of 2 quarters · filed 2023-11-07 | 3.40M shares 10-Q · filed 2023-11-07 | 3.48M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 286.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 3.26M shares 10-Q · filed 2023-08-08 | 3.35M shares derived: sum of 3 quarters · filed 2023-08-08 | 3.42M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 2.98M shares 10-Q · filed 2023-05-08 | 3.07M shares derived: sum of 2 quarters · filed 2023-05-08 | 3.13M shares derived: sum of 3 quarters · filed 2023-05-08 | 3.40M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 87.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 156.25K shares derived: sum of 2 quarters · filed 2023-02-27 | 425.67K shares derived: sum of 3 quarters · filed 2023-02-27 | 2.26M shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 68.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 337.92K shares derived: sum of 2 quarters · filed 2022-11-03 | 2.17M shares 10-Q · filed 2022-11-03 | 2.26M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 269.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 2.10M shares 10-Q · filed 2022-08-08 | 2.19M shares derived: sum of 3 quarters · filed 2022-08-08 | 2.37M shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 1.83M shares 10-Q · filed 2022-05-05 | 1.92M shares derived: sum of 2 quarters · filed 2022-05-05 | 2.10M shares derived: sum of 3 quarters · filed 2022-05-05 | 2.23M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 93.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 269.40K shares derived: sum of 2 quarters · filed 2022-02-28 | 398.68K shares derived: sum of 3 quarters · filed 2022-02-28 | 2.04M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 176.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 305.68K shares derived: sum of 2 quarters · filed 2021-11-04 | 1.94M shares 10-Q · filed 2021-11-04 | 2.09M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 129.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 1.77M shares 10-Q · filed 2021-08-04 | 1.92M shares derived: sum of 3 quarters · filed 2021-08-04 | 2.04M shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 1.64M shares 10-Q · filed 2021-05-05 | 1.79M shares derived: sum of 2 quarters · filed 2021-05-05 | 1.91M shares derived: sum of 3 quarters · filed 2021-05-05 | 2.16M shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 147.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 274.00K shares derived: sum of 2 quarters · filed 2021-02-26 | 519.71K shares derived: sum of 3 quarters · filed 2021-02-26 | 3.52M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 126.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 372.46K shares derived: sum of 2 quarters · filed 2020-11-05 | 3.37M shares 10-Q · filed 2020-11-05 | 3.46M shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 245.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 3.24M shares 10-Q · filed 2020-08-07 | 3.33M shares derived: sum of 3 quarters · filed 2020-08-07 | 3.56M shares derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | 3.00M shares 10-Q · filed 2020-05-07 | 3.09M shares derived: sum of 2 quarters · filed 2020-05-07 | 3.31M shares derived: sum of 3 quarters · filed 2020-05-07 | 3.86M shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 90.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 314.50K shares derived: sum of 2 quarters · filed 2020-02-27 | 865.09K shares derived: sum of 3 quarters · filed 2020-02-27 | 3.61M shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 224.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 774.84K shares derived: sum of 2 quarters · filed 2019-11-06 | 3.52M shares 10-Q · filed 2019-11-06 | 3.88M shares derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | 550.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 3.30M shares 10-Q · filed 2019-08-06 | 3.65M shares derived: sum of 3 quarters · filed 2019-08-06 | 4.28M shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 2.75M shares 10-Q · filed 2019-05-08 | 3.10M shares derived: sum of 2 quarters · filed 2019-05-08 | 3.73M shares derived: sum of 3 quarters · filed 2019-05-08 | 4.14M shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | 358.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | 985.54K shares derived: sum of 2 quarters · filed 2019-03-12 | 1.39M shares derived: sum of 3 quarters · filed 2019-03-12 | 3.95M shares 10-K · filed 2019-03-12 |
| 2018-09-30 | 627.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 1.04M shares derived: sum of 2 quarters · filed 2018-11-08 | 3.59M shares 10-Q · filed 2018-11-08 | |
| 2018-06-30 | 408.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 2.96M shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 2.56M shares 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | 2.18M shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |